1. Ferlay J,
Shin HR,
Bray F,
et al.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
International journal of cancer 2010; 127(12): 2893-917.
2. Kwee TC,
Takahara T,
Katahira K,
et al.
Whole-body MRI for detecting bone marrow metastases.
PET Clin.
2010;5:297-309.
3. Coleman R.
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity.
Clin Cancer Res 2006;12(20 Suppl)
4. Bohm P,
Huber J.
The surgical treatment of bony metastases of the spine and limbs.
J Bone Joint Surg Br 2002;84:521-9.
5. Wong DA,
Fornasier VL,
MacNab I.
Spinal metastases: the obvious,
the occult,
and the impostors. Spine 1990;15:1-4.
6. Coleman RE.
Metastatic bone disease: clinical features,
pathophysiology and treatment strategies.
Cancer Treat Rev 2001; 27(3):165-76.
7. Shah LM,
Hanrahan CJ.
MRI of spinal bone marrow: part I,
tech- niques and normal age-related appearances.
AJR Am J Roent- genol.
2011;197:1298-308.
8. Padhani AR,
Koh DM,
Collins DJ.
Whole-body diffusion-weighted MR Imaging in cancer: Current status and research directions.
Radiology.
2011;261:700-18.
9. Barragán-Campos HM,
Jiménez-Zarazúa O,
Mondragón JD.
Diagnosis and treatment options of spinal metastases.
Rev Inves Clin.
2015;67(3):140-57.
10. Poulsen M,
Petersen H,.
Høilund-Carlsen P,
Jakobsen J,
Gerke O,
Karstoft J,
Steffansen S,
Walter S.
Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy,
[18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT.
BJU International.
2014;114:818-823.
11. Beheshti M,
Langsteger W.
18 FNaF PET/CT in the assessment of metastatic bone disease: Comparison with specific PET tracers.
PET Clin.
2012;7:303-14.
12. Roodman GD.
Mechanisms of bone metastasis New England Journal of Medicine,
2004: 350:1655-64.
13. Irwig L,
Tosteson N,
Gastonis C,
Lau J,
Colditz G,
Chalmers T,
Mosteller F.
Guidelines for Meta-analyses Evaluating Diagnostic Test.
Ann Intern Med 1994;120:667-676
14. Dill T.
Contraindications to magnetic resonance imaging.
Heart 2008;94:943-948.
15. Kwee T,
Takahara T,
Ochiai R,
Nievelstein R,
Luijten P.Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology.
Eur Radiol (2008) 18: 1937-1952.
16. Bastawrous S,
Bhargava P,
Behnia F,
Djang D,
Haseley D.
Newer PET application with an old Tracer: Role of 18F-NaF skeletal PET/CT in Oncologic Practice.
Radiographics.
2014; 12 95-1365.
17. Gianfelice D,
Gupta C,
Kucharczyk W,
Bret P,
Havill D,
Clemons M.
Palliative Treatment of Painful Bone Metastases with MR Imaging–guided Focused Ultrasound.
2008;249: 355–363.
18. S,
JainP,
Jethwa S,
Tripathy D,
Yamashita M.
Radiologist’s Role in Breast Cancer Staging: Providing Key Information for Clinicians.
RadioGraphics 2014; 34:330–342
19. Stewart A.
Hypercalcemia associated with cancer.
N Engl J Med 2005; 352:373-379
20. Brown J,
Cook R,
Major P,
Lipton A,
Saad F,Smith M,
Lee K,
Zheng M,
Hei Y,
Coleman R.Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer,
Lung Cancer,
and Other Solid Tumors.
JNCI J Natl Cancer Inst (2005) 97 (1): 59-69.